Moreover, ALCAM-specific CAR-T cells can efficiently lyse CRC cells and show powerful cytotoxicity against CRC stem cells, demonstrating a feasible approach for reconstructing CAR-T cells with S100A8/A9 and its receptors for cancer therapy (He et al., 2023). This evidence concerns the gene IGKV1D-22 and cancer.